Form 8-K · Current report
Viatris 8-K, filed Nov 5, 2026
- Filed
- CIK
- 0001792044
- Accession no.
- 0001792044-26-000053
Summary
Viatris reported third-quarter 2026 total revenues of $3.75 billion, a U.S. GAAP net loss of $325 million, and adjusted EBITDA of $1.20 billion, and raised its 2026 financial guidance midpoints for all metrics. It also announced U.S. approval of RYZUMVI for presbyopia, Japan approval of WAKIX for excessive daytime sleepiness associated with obstructive sleep apnea syndrome and narcolepsy, and a planned $1.65 billion acquisition of Pacira BioSciences at $36.50 per share in cash expected to close by the end of November 2026.
Key points
- Viatris reported third-quarter 2026 total revenues of $3.75 billion, essentially flat year over year, a U.S. GAAP net loss of $325 million, adjusted EBITDA of $1.20 billion and adjusted EPS of $0.71, and raised its 2026 guidance midpoints for all metrics.
- Viatris launched Gwyn Lo in the U.S. in October, the FDA approved RYZUMVI for presbyopia in adults, and Japan's Ministry of Health, Labour and Welfare approved WAKIX for excessive daytime sleepiness associated with obstructive sleep apnea syndrome and for narcolepsy.
- Viatris agreed to acquire all outstanding shares of Pacira BioSciences for $36.50 per share in cash, an aggregate equity value of $1.65 billion, with the deal expected to close by the end of November 2026.
- After the FDA classified its Nashik, India oral solid dose manufacturing facility as Official Action Indicated, Viatris voluntarily suspended manufacturing there in October and expects to resume production in the first quarter of 2027; it estimated the total revenue impact of supply constraints at approximately $100 million.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 8.01Other Events
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02 Results of Operations and Financial Condition. On November 5, 2026, Viatris Inc. (“Viatris” or the “Company”) issued a press release reporting the Company's financial results for the period ended September 30, 2026. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities…
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.